10-Year hepatitis study aims to unlock secrets of liver disease

NCT ID NCT02995252

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study follows people with chronic hepatitis B or C for up to 10 years to track how the disease changes over time. A smaller group with hepatitis B will receive the drug tenofovir alafenamide for 2 years to see if it reduces liver stiffness. Participants provide blood samples and may have optional liver biopsies or FibroScans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tenofovir alafenamide
What this could lead to
If successful, this could help doctors better understand how hepatitis B and C progress over time and whether tenofovir alafenamide can reduce liver stiffness.
What could go wrong
This is an observational study with a small treatment sub-study, so results may not apply to everyone. The treatment may not improve liver health for all participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dr Huong Dang, Medical Practice

    Falls Church, Virginia, 22044, United States

  • Institute of Human Virology, University of Maryland School of Medicine

    Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.